My son, Sal, was a bright and loving 20-year-old young man who, like many others, was navigating the complexities of growing up neurodivergent. He started taking an SSRI antidepressant prescribed by our family physician, as he was struggling with work, school, and life. But less than three weeks after starting the medication, Sal took his own life. His story is not unique, and it reflects a broader, more urgent issue.

Neurodivergence encompasses a range of conditions like autism, ADHD, and others that affect the way individuals experience the world. Many individuals living with these conditions are prescribed psychotropic medications, including Selective Serotonin Reuptake Inhibitors (SSRIs). However, there is still a significant gap in our understanding of how these medications specifically interact with neurodivergent brains. Current prescribing practices often rely on general guidelines that don't account for the unique neurological profiles of neurodivergent individuals.

Neurodiverse young people have a significantly higher rate of suicidality compared to their neurotypical peers. Studies indicate elevated risks of suicidal ideation, suicide attempts, and death by suicide for young people with autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). The risks are even higher for those with co-occurring neurodevelopmental conditions.

It's critical that we push for more focused and dedicated studies on the effects of psychotropic medications, including SSRIs, on neurodivergent individuals. We must advocate for focused research on the effects of SSRIs on neurodivergent individuals to ensure safer, more effective treatments. This includes specific prescribing protocols including:

• Early & frequent monitoring
• More screening questions
• Increased referrals to specialists.

By advocating for enhanced research and better protocols, we aim to ensure safer, more effective treatment options that accommodate the diverse needs of all patients. A deeper understanding could reduce the risks of adverse effects and improve the well-being of countless individuals and families.

Concrete steps can be taken to advance our knowledge in this area. We urge the National Institute of Mental Health, pharmaceutical companies, and relevant stakeholders to prioritize and allocate funding for research explicitly examining the impact of SSRIs on neurodivergent populations. Additionally, collaboration with neurodiversity experts can help guide study designs that are attentive to the unique challenges these individuals face.

The tragic loss of Sal, and many others like him, underscores the urgency of this issue. We need to prevent further tragedies like the loss of Sal. Help us to drive change and ensure medications designed to help do not inadvertently cause harm to the neurodivergent community. We must act now to prevent further heartache.

Your signature can drive the change needed to prioritize this vital research. Stand with us in safeguarding the future of neurodivergent individuals who rely on these medications.
 

View this video to learn more "Do You Read the Small Print?"